PSA Pharma: Eisai (4523 JT) / Biogen (BIIB US) End Elenbecestat Trials
For the past year or so Pelham Smithers has considered the pharma sector to be unattractive. Here he considers whether Eisai might make an investment candidate.Eisai is mainly engaged in the manufacture and sale of pharmaceutical products. Co.'s principal prescription drugs include anticancer agents, anti-Alzheimer's agent, anti-TNF monoclonal antibodies, antiepileptic agents, proton pump inhibitors, neuropathic pain relievers, and other prescription drugs under the name of "Halaven," "Lenvima," "Fycompa," "BELVIQ," "Pariet/AcipHex," "Aricept," and "Humira." Co.'s principal over-the-counter products include Vitamin B2 preparations "Chocola BB," gastrointestinal drugs, anti-allergic drugs, and dermatological preparations. Co. operates its operations in Japan, the Americas, Europe, China and Asia.
Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods.
PSA produces both company and sector reports. The focus of PSA’s research is to identify winners and losers as new technologies impact the top and bottom lines of corporations. Critical to our research is the clear explanation of how these new technologies work and how they impact companies and industries.
The founding partners have worked closely together for twenty years and the team has more than doubled in size since 2012.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.